News Detail
Maryland, 12 Feb 2025: A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. have landed in the FDA’s crosshairs thanks to quality shortfalls, poor testing standards and more.
The FDA earlier t......
View Details
Source : Fierce Pharma
U.S. FDA
FDA warning letter
FDA inspection
active pharmaceutical ingredients
drug manufacturing
Manufacturing Facilities
China
import alert
Facilities
Fierce Pharma Homepage
Pharma
Manufacturing
Related News
- Enforce regulations, strengthen penalties to fight the menace of counterfeit drugs: Parliamentary Panel (25-03-2025)
- Supplement firm Bioventra warns of online fakes (25-03-2025)
- FDA drug approvals drops, but smaller pharma leads innovation: GlobalData (25-03-2025)
- No staff involved in promoting fake drugs, vaccination: Odisha Health Minister (25-03-2025)
- Centre to introduce standardised hospital billing format to ensure transparency (24-03-2025)
- CDSCO asks MSME pharma firms to apply online for Schedule M extension (24-03-2025)
- Father and son arrested for unlicensed medicine sales, concealed drugs in cowshed (24-03-2025)
- AI-driven device by PGI set to transform neuropathic pain diagnosis (24-03-2025)
- Chhattisgarh EOW Arrests Five Officers in ₹660 Cr Procurement Scam (24-03-2025)
- Man caught at Silchar Medical College for allegedly overpricing medicines (24-03-2025)